Prostate Cancer Clinical Trial
Official title:
CHESS: Human and Computer Mentors for Prostate Cancer Patients
The aims include:
1. To measure the effect of the three study conditions on Quality of Life (QOL).
- CHESS and Cancer Information Mentor will not differ initially (6 weeks) or late in
treatment (6 months) in QOL
- CHESS +Cancer Information Mentor will have the largest impact on QOL (initially and
late in treatment) and will be significantly better than either CHESS or Cancer
Information Mentor alone.
2. To measure potential intervening or mediating processes, so that we can determine how
CHESS and the Cancer Information Mentor produce associated QOL benefits.
3. To conduct exploratory use analyses examining which types of CHESS content, sequential
patterns of content use, or other characteristics of use behavior are associated with
greater pretest-posttest improvements in QOL.
4. To conduct a secondary analysis exploring whether men whose partners have actively used
CHESS do better than those whose partners did not use CHESS.
CHESS and Cancer Information Mentoring:
Researchers want to learn the best way to improve a man with prostate cancer's knowledge,
coping skills, and satisfaction with decision-making and overall quality of life. This study
will do this by comparing the following 3 methods of receiving information, social support,
and skill training: using the CHESS system for 6 months, talking to a Cancer Information
Mentor for 6 months, or using the CHESS system and talking to a Cancer Information Mentor for
6 months.
CHESS is an interactive, internet-based computer program that will provide information,
social support, and skill-building techniques. CHESS provides the latest medical, social, and
legal information about prostate cancer (such as information on symptoms and treatments). It
also provides help in deciding what treatment to choose, advice on where participants can go
for help, information on how participants can make the best use of health and human services,
and a way for participants to share concerns with cancer information specialists and other
survivors of prostate cancer. Participants who take part in the CHESS interactive services
will not need to give their names. Participants can talk with other people by sending
anonymous (your identity will be unknown) messages through the CHESS computer network.
Cancer Information Mentoring is provided by a person called a "cancer information mentor"
that will give quality prostate cancer information and explain medical information and
procedures. The cancer information mentor is a certified information specialist trained by
the National Cancer Institute (NCI). This mentor will not provide medical advice or mental
health counseling.
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the roll of
dice) to 1 of 3 groups. No matter which group you are assigned to, you will be loaned a
computer with internet access to use in your own home (unless you have your own computer and
would prefer to use it). The computer will be sent to your home, and you will be trained on
how to use the computer and the CHESS system.
Participants in Group 1 will have access to the CHESS system. Participants in Group 2 will
talk with a cancer information mentor. Participants in Group 3 will have access to the CHESS
system and talk with a cancer information mentor.
Study Participation:
CHESS Participants in Group 1 and Group 3 who receive the CHESS internet-based program will
have access to information, social support, and skill-building services. The CHESS system
will keep a record of how often and for how long each part of CHESS is used. Information will
also be gathered about anything you communicate in the CHESS interactions. This information
will be used to figure out which parts of CHESS may be most useful. You will be provided a
free 1-800 phone number for computer support if you need any help.
Cancer Information Mentoring:
Patients in Group 2 and Group 3 will have access to a cancer information mentor. The mentor
will make regular telephone calls to the patient during the study. He will receive 10 calls
in total (4 calls the first month, 2 calls the second month, and one call each in Months
3-6). Patients can also call the cancer information mentor whenever they wish during this
period. Each call will last as long as the patient needs it to.
For patients in Group 3, the cancer information mentor will communicate with them through
CHESS as well as by telephone.
Surveys:
All participants will fill out 5 surveys during this study. The surveys will include
questions about health, treatment decisions, knowledge of prostate cancer, and quality of
life. You will complete the first survey before you get the computer and again at 2 weeks, 6
weeks, 3 months, and 6 months after getting the computer. The surveys should take about 30
minutes to finish each time.
Length of Study:
This study will last up to a little over 6 months (about 24 weeks).
Up to 327 men and 327 support persons will take part in this multicenter study. Up to 127
participants and 127 support persons will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |